Octreotide Dosing and Monitoring for Persistent or Recurrent Hypoglycemia
Octreotide is used for persistent or recurrent hypoglycemia from insulinoma or sulfonylurea-associated hypoglycemia after correction with dextrose. (albertahealthservices.ca)
Insulinoma-Associated Hypoglycemia (Persistent or Recurrent)
Fast-acting octreotide can be used as a monitored trial for insulinoma-related hypoglycemia due to risk of paradoxical worsening in selected patients. (albertahealthservices.ca)
Medication Selection Algorithm
- Short-acting octreotide (SC) is used for initial symptomatic control with monitoring in insulinoma. (albertahealthservices.ca)
- Long-acting octreotide (IM depot) is used for ongoing control after response to fast-acting octreotide. (albertahealthservices.ca)
Recommended Dosing Regimens
- Fast-acting octreotide: a monitored trial of 100–250 mcg SC 2–3 times daily for 1–2 weeks is suggested for tolerability, followed by long-acting somatostatin analog therapy for ongoing control. (albertahealthservices.ca)
- For insulinomas, the first fast-acting octreotide SC dose should be given in a monitored setting due to possible paradoxical hypoglycemia. (albertahealthservices.ca)
- Dose and frequency of fast-acting octreotide may be increased for symptom control as needed. (albertahealthservices.ca)
Long-Acting Somatostatin Analog Transition
- Long-acting octreotide (Sandostatin LAR or Teva-octreotide): 10–30 mg IM every 4 weeks is provided as dosing for symptom control. (albertahealthservices.ca)
Monitoring Strategy
- Initial dosing should occur in a monitored setting for insulinoma to detect paradoxical hypoglycemia. (albertahealthservices.ca)
- Blood glucose monitoring frequency for dose response is determined by clinical status during the monitored trial period. (albertahealthservices.ca)
Sulfonylurea-Associated Hypoglycemia (Overdose) With Recurrent Hypoglycemia
Octreotide is used after initial correction of hypoglycemia with dextrose to prevent recurrence due to ongoing sulfonylurea-driven insulin secretion. (poisoncontrol.utah.edu)
Recommended Dosing Regimens
- Adults (age >12 years): 50 mcg SC per dose. (poisoncontrol.utah.edu)
- Children (ages 6–12 years): 25 mcg SC per dose. (poisoncontrol.utah.edu)
- Children (age <6 years): 10 mcg SC per dose. (poisoncontrol.utah.edu)
- Pediatrics dosing alternative: 1.0 to 1.5 mcg/kg SC every 6 hours. (poisoncontrol.utah.edu)
Dose Repetition Interval for Recurrence
- Octreotide effect after a single SC dose lasts approximately 6 to 8 hours. (poisoncontrol.utah.edu)
- If hypoglycemia recurs, a repeat octreotide dose may be needed every 6 hours. (poisoncontrol.utah.edu)
- Large ingestions may require scheduled octreotide every 6 hours for 24 hours. (poisoncontrol.utah.edu)
Monitoring Strategy
- Monitoring for 12 to 24 hours after the last octreotide dose is recommended because recurrence can occur. (poisoncontrol.utah.edu)
- If not discharged after an octreotide injection, the suggested monitoring approach includes blood glucose checks every hour for 3 checks, then every 4 hours if awake and asymptomatic. (poisoncontrol.utah.edu)
- If signs of hypoglycemia occur at any time, immediate bedside finger-stick glucose measurement is recommended. (poisoncontrol.utah.edu)
Key Evidence Supporting These Regimens
The use of octreotide for sulfonylurea-induced hypoglycemia is supported by clinical summaries describing a commonly used regimen of an initial 50 mcg dose repeated 2–3 times daily in selected settings. (pmc.ncbi.nlm.nih.gov)
Common Pitfalls to Avoid
Paradoxical worsening of hypoglycemia is a recognized risk in insulinoma when initiating octreotide, so initial dosing should occur in a monitored setting. (albertahealthservices.ca)
Safety Monitoring for Adverse Effects During Treatment
Monitoring for clinical recurrence of hypoglycemia is required after sulfonylurea overdoses because rebound episodes can occur after stopping octreotide. (poisoncontrol.utah.edu)